Туберкулез и болезни лёгких (Aug 2020)

The multivariate analysis of results of bedaquiline use in the therapy of MDR/XDR pulmonary tuberculosis

  • N. V. Stavitskaya,
  • I. G. Felker,
  • E. M. Zhukova,
  • А. I. Tlif,
  • N. P. Doktorova,
  • D. А. Kudlay

DOI
https://doi.org/10.21292/2075-1230-2020-98-7-56-62
Journal volume & issue
Vol. 98, no. 7
pp. 56 – 62

Abstract

Read online

The objective of the study: to perform the multivariate analysis of treatment outcomes in patients with multiple/extensive drug resistant tuberculosis (MDR/XDR TB), including those with HIV infection, whose chemotherapy regimens included bedaquiline. Subjects and methods: 70 patients with MDR/XDR TB were enrolled in the retrospective two-center study, the multivariate analysis of treatment outcomes with bedaquiline-containing regimen was carried out. Results: the performed multivariate analysis demonstrated high efficacy and good tolerability of bedaquiline-containing regimens for MDR/XDR TB treatment even despite the continuous ineffective treatment of patients in the past. The prolonged intake of bedaquiline for more than 24 weeks was not associated with a high level of adverse reactions. It was found that the use of cycloserine/terizidone made a significant contribution to the favorable outcome of chemotherapy. The factors associated with the most unfavorable treatment outcomes were the following: age above 60 years, concurrent chronic obstructive pulmonary disease, alcohol and/or drug addiction, and smoking.

Keywords